Patient characteristics at baseline
Characteristic . | Value . |
---|---|
No. of subjects enrolled | 60 |
Median age, y (range) | 70.1 (40.4-87.2) |
Sex, n (%) | |
Male | 28 (46.7) |
Female | 32 (53.3) |
Race, n (%) | |
White | 53 (88.3) |
Black | 4 (6.7) |
Hispanic | 2 (3.3) |
Other | 1 (1.7) |
Eastern Cooperative Oncology Group performance status* | |
0 | 33 (55.0) |
1 | 27 (45.0) |
Laboratory values | |
Normal hemoglobin | 35 (58.3) |
Normal LDH | 44 (73.3) |
Stage | |
IE-IIE | 4 (6.7) |
III | 15 (25.0) |
IIIE | 2 (3.3) |
IV | 39 (65.0) |
Histology | |
Follicular center cell, grade 1 | 23 (38.3) |
Follicular center cell, grade 2 | 17 (28.3) |
Small lymphocytic | 12 (20.0) |
Marginal zone, extranodal | 5 (8.3) |
Marginal zone, nodal | 2 (3.3) |
Unspecified | 1 (1.7) |
Prior therapy† | |
Chemotherapy | 60 (100) |
Hormone/biologic therapy | 1 (1.7) |
Radiotherapy | 13 (21.7) |
Sites of metastasis‡ | |
Soft tissue/lymph node(s) | 59 (98.3) |
Viscera | 21 (35.0) |
Bone | 16 (26.7) |
Characteristic . | Value . |
---|---|
No. of subjects enrolled | 60 |
Median age, y (range) | 70.1 (40.4-87.2) |
Sex, n (%) | |
Male | 28 (46.7) |
Female | 32 (53.3) |
Race, n (%) | |
White | 53 (88.3) |
Black | 4 (6.7) |
Hispanic | 2 (3.3) |
Other | 1 (1.7) |
Eastern Cooperative Oncology Group performance status* | |
0 | 33 (55.0) |
1 | 27 (45.0) |
Laboratory values | |
Normal hemoglobin | 35 (58.3) |
Normal LDH | 44 (73.3) |
Stage | |
IE-IIE | 4 (6.7) |
III | 15 (25.0) |
IIIE | 2 (3.3) |
IV | 39 (65.0) |
Histology | |
Follicular center cell, grade 1 | 23 (38.3) |
Follicular center cell, grade 2 | 17 (28.3) |
Small lymphocytic | 12 (20.0) |
Marginal zone, extranodal | 5 (8.3) |
Marginal zone, nodal | 2 (3.3) |
Unspecified | 1 (1.7) |
Prior therapy† | |
Chemotherapy | 60 (100) |
Hormone/biologic therapy | 1 (1.7) |
Radiotherapy | 13 (21.7) |
Sites of metastasis‡ | |
Soft tissue/lymph node(s) | 59 (98.3) |
Viscera | 21 (35.0) |
Bone | 16 (26.7) |